Skip to main content
H. Lundbeck A logo

H. Lundbeck A — Investor Relations & Filings

Ticker · HLUN ISIN · DK0061804770 LEI · 5493006R4KC2OI5D3470 CO Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2026-02-04 Earnings Release
Country DK Denmark
Listing CO HLUN

About H. Lundbeck A

https://www.lundbeck.com/global

H. Lundbeck A/S is a global biopharmaceutical company specializing in brain diseases. The company is engaged in the research, development, manufacturing, and marketing of transformative therapies for a range of psychiatric and neurological disorders. Its portfolio and pipeline focus on conditions such as depression, mood disorders, and rare childhood-onset epilepsies. Lundbeck is dedicated to advancing neuroscience to improve the quality of life for individuals affected by central nervous system disorders.

Recent filings

Filing Released Lang Actions
Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026
Earnings Release Classification · 95% confidence The document is a corporate press release detailing financial performance for the fiscal year 2025, including revenue, EBITDA, and EPS figures. It highlights key strategic brands and recent events. While it contains financial data, it is structured as an initial announcement of results (Earnings Release) rather than a full 10-K or Interim Report. The document concludes with a link to a separate PDF file titled 'Corporate Release FY2025 Final', confirming this text is the summary announcement. FY 2025
2026-02-04 English
Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026
Earnings Release Classification · 100% confidence The document is a 'Corporate release' detailing Lundbeck's financial performance for the fiscal year 2025. It includes key highlights, revenue breakdowns, EBITDA, and EPS figures. Crucially, the text explicitly states: 'This Corporate release should not be seen as a financial report in accordance with IAS 34 – Interim Financial Reporting' and 'The Annual Report comprising the financial statements for the year ended 31 December 2025, is available for download on: lundbeck.com on 4 February 2026.' This confirms the document is an initial announcement of financial results (Earnings Release) rather than the full Annual Report or an Interim Report. FY 2025
2026-02-04 English
Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Director's Dealing Classification · 100% confidence The document is a formal notification of a share transaction by an executive (Barendina Hol, Executive Vice President) of H. Lundbeck A/S. It explicitly details the nature of the transaction (sale of shares), the price, volume, and the date of the transaction. This aligns perfectly with the definition of a 'Director's Dealing' (DIRS) filing, which covers personal share transactions by company directors and executives.
2025-12-08 Danish
Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Director's Dealing Classification · 100% confidence The document is a formal notification of a share transaction by an executive (Barendina Hol, Executive Vice President) of H. Lundbeck A/S. It follows the standard regulatory format for reporting insider dealings, including the name of the person discharging managerial responsibilities, the nature of the transaction (sale of shares), the price, volume, and the date of the transaction. This fits the definition of a Director's Dealing (DIRS) filing.
2025-12-08 English
ANNOUNCEMENT FOR THE PURPOSES OF ARTICLE 17 "MAR" RULES (EU) NO. 596/2014 (INSIDE INFORMATION) AND RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”)
M&A Activity Classification · 100% confidence The document is a formal corporate announcement from H. Lundbeck A/S regarding its decision not to proceed with an offer for Avadel Pharmaceuticals plc. It explicitly references 'Rule 2.8 of the Irish Takeover Rules', which governs statements of intent regarding potential acquisitions or takeovers. Since this document details the termination of a potential M&A process and the resulting regulatory restrictions, it falls under the M&A Activity category.
2025-12-01 English
ANNOUNCEMENT FOR THE PURPOSES OF ARTICLE 17 MARKET ABUSE REGULATION (EU) NO. 596/2014 (INSIDE INFORMATION) AND RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER
M&A Activity Classification · 100% confidence The document is a formal corporate announcement from H. Lundbeck A/S regarding the decision not to make an offer for Avadel Pharmaceuticals plc. It explicitly references 'Rule 2.8 of the Irish Takeover Rules', which governs statements of intent regarding potential acquisitions. This falls under the category of M&A activity, specifically an announcement regarding the termination of a potential takeover bid.
2025-12-01 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.